Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physicians. Urol Oncol. 2012;30(2):155-160.Tasian GE, Cooperberg MR, Cowan JE, et al. Prostate specific antigen screening for prostate cancer: Knowledge of, attitudes ...
the use of PSA has also led to over-diagnosis and over-treatment of prostate cancer resulting in controversy about its use for screening. Prostate specific antigen also has limited predictive accuracy for predicting outcomes after
Prostate-Specific Antigen–Based Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Resaerch and Quality; October 2011. AHRQ publication 12-05160-EF-1. 9. Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of ...
Prostate-specific antigen-based screening: controversy and guidelines. BMC Med. 13, 61.Kim EH, Andriole GL. Prostate-specific antigen-based screen- ing: Controversy and guidelines. BMC Med 2015;13(1):61.Kim EH and Andriole GL. Prostate-specific antigen-based screening: controversy and guidelines...
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context: Draisma G, Etzioni R, Tsodikov A, et al (Univ Med Ctr, Rotterdam, The Netherlands) J Natl Cancer Inst 101:374-383, 2009§ 2009, Yearbook of Urology more A.S. Kibel Lead time and ...
Cells in your prostate make a protein called prostate-specific antigen (PSA). APSAblood test measures the amount of PSA you have circulating in your blood. The amount of PSA your cells make tends to go up as you get older, but it can also be high in people with: ...
Prostate-Specific Antigen–Based Screening for Prostate Cancer: A Systematic Evidence Review for the US Preventive Services Task Force: Evidence Synthesis No. 154. Rockville, MD: Agency for Healthcare Research and Quality; 2018. AHRQ publication 17-05229-EF-1. 4. Fenton JJ, Weyrich MS, Durbin ...
Prostate-specific antigen screening results in overdetection (of cases that would not otherwise have been detected) and introduces a lead time (the time difference between screen detection and clinical detection in the absence of screening), which may be of the order of 10 years or more (Drais...
Cells in your prostate make a protein called prostate-specific antigen (PSA). APSAblood test measures the amount of PSA you have circulating in your blood. The amount of PSA your cells make tends to go up as you get older, but it can also be high in people with: ...
Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition to PrCa due to BRCA1/2 mutations. This analysis evaluates the utility of PSA an...